Annual Total Expenses
$55.03 M
-$5.62 M-9.26%
31 December 2023
Summary:
Protalix BioTherapeutics annual total expenses is currently $55.03 million, with the most recent change of -$5.62 million (-9.26%) on 31 December 2023. During the last 3 years, it has fallen by -$3.78 million (-6.42%). PLX annual total expenses is now -15.86% below its all-time high of $65.41 million, reached on 31 December 2019.PLX Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Expenses
$13.97 M
-$1.93 M-12.16%
30 September 2024
Summary:
Protalix BioTherapeutics quarterly total expenses is currently $13.97 million, with the most recent change of -$1.93 million (-12.16%) on 30 September 2024. Over the past year, it has dropped by -$2.13 million (-13.25%). PLX quarterly total expenses is now -22.77% below its all-time high of $18.09 million, reached on 30 June 2019.PLX Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PLX Total Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -13.3% |
| 3 y3 years | -6.4% | -2.0% |
| 5 y5 years | -15.9% | -10.2% |
PLX Total Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -9.3% | at low | -22.2% | +62.3% |
| 5 y | 5 years | -15.9% | at low | -22.2% | +62.3% |
| alltime | all time | -15.9% | >+9999.0% | -22.8% | >+9999.0% |
Protalix BioTherapeutics Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $13.97 M(-12.2%) |
| June 2024 | - | $15.90 M(+84.8%) |
| Mar 2024 | - | $8.60 M(-46.6%) |
| Dec 2023 | $55.03 M(-9.3%) | $16.10 M(+31.6%) |
| Sept 2023 | - | $12.23 M(-16.5%) |
| June 2023 | - | $14.65 M(+21.6%) |
| Mar 2023 | - | $12.05 M(+8.4%) |
| Dec 2022 | $60.65 M(+3.1%) | $11.11 M(-35.8%) |
| Sept 2022 | - | $17.31 M(+21.2%) |
| June 2022 | - | $14.28 M(-20.5%) |
| Mar 2022 | - | $17.95 M(+26.0%) |
| Dec 2021 | $58.81 M(-2.3%) | $14.26 M(+2.3%) |
| Sept 2021 | - | $13.94 M(-10.6%) |
| June 2021 | - | $15.59 M(+3.8%) |
| Mar 2021 | - | $15.03 M(-9.8%) |
| Dec 2020 | $60.19 M(-8.0%) | $16.66 M(+24.6%) |
| Sept 2020 | - | $13.37 M(+1.2%) |
| June 2020 | - | $13.21 M(-22.1%) |
| Mar 2020 | - | $16.95 M(+9.0%) |
| Dec 2019 | $65.41 M(+22.2%) | $15.56 M(-1.5%) |
| Sept 2019 | - | $15.79 M(-12.7%) |
| June 2019 | - | $18.09 M(+13.2%) |
| Mar 2019 | - | $15.97 M(+13.9%) |
| Dec 2018 | $53.55 M(-3.7%) | $14.03 M(-12.8%) |
| Sept 2018 | - | $16.08 M(+38.8%) |
| June 2018 | - | $11.58 M(-2.4%) |
| Mar 2018 | - | $11.87 M(-14.6%) |
| Dec 2017 | $55.59 M(+31.2%) | $13.89 M(-9.2%) |
| Sept 2017 | - | $15.29 M(-10.9%) |
| June 2017 | - | $17.16 M(+85.5%) |
| Mar 2017 | - | $9.25 M(-14.3%) |
| Dec 2016 | $42.36 M(+51.1%) | $10.80 M(-4.6%) |
| Sept 2016 | - | $11.32 M(-3.3%) |
| June 2016 | - | $11.70 M(+37.0%) |
| Mar 2016 | - | $8.54 M(+10.9%) |
| Dec 2015 | $28.03 M(-12.6%) | $7.70 M(+21.5%) |
| Sept 2015 | - | $6.34 M(-8.4%) |
| June 2015 | - | $6.92 M(-2.2%) |
| Mar 2015 | - | $7.08 M(+3766.7%) |
| Dec 2014 | $32.08 M(-5.8%) | $183.00 K(-98.2%) |
| Sept 2014 | - | $9.91 M(+21.9%) |
| June 2014 | - | $8.13 M(-41.3%) |
| Mar 2014 | - | $13.85 M(+106.6%) |
| Dec 2013 | $34.06 M(-26.9%) | $6.70 M(-25.5%) |
| Sept 2013 | - | $9.00 M(-9.6%) |
| June 2013 | - | $9.96 M(+18.6%) |
| Mar 2013 | - | $8.40 M(-17.8%) |
| Dec 2012 | $46.60 M(+18.0%) | $10.21 M(-6.7%) |
| Sept 2012 | - | $10.95 M(-30.0%) |
| June 2012 | - | $15.64 M(+59.7%) |
| Mar 2012 | - | $9.79 M(+2.6%) |
| Dec 2011 | $39.50 M | $9.55 M(-1.2%) |
| Sept 2011 | - | $9.66 M(+4.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2011 | - | $9.25 M(-16.2%) |
| Mar 2011 | - | $11.04 M(-24.5%) |
| Dec 2010 | $41.21 M(+27.4%) | $14.63 M(+142.5%) |
| Sept 2010 | - | $6.03 M(-44.0%) |
| June 2010 | - | $10.76 M(+20.0%) |
| Mar 2010 | - | $8.97 M(-41.8%) |
| Dec 2009 | $32.36 M(+33.9%) | $15.40 M(+154.8%) |
| Sept 2009 | - | $6.05 M(+2.9%) |
| June 2009 | - | $5.87 M(+16.6%) |
| Mar 2009 | - | $5.04 M(-20.0%) |
| Dec 2008 | $24.17 M(-29.3%) | $6.29 M(-6.3%) |
| Sept 2008 | - | $6.72 M(+37.2%) |
| June 2008 | - | $4.90 M(-21.8%) |
| Mar 2008 | - | $6.26 M(-59.9%) |
| Dec 2007 | $34.16 M(+249.6%) | $15.62 M(+142.8%) |
| Sept 2007 | - | $6.43 M(-31.1%) |
| June 2007 | - | $9.34 M(+146.9%) |
| Mar 2007 | - | $3.78 M(+1.2%) |
| Dec 2006 | $9.77 M(+64.5%) | $3.73 M(+47.2%) |
| Sept 2006 | - | $2.54 M(-27.5%) |
| June 2006 | - | $3.50 M(+113.7%) |
| Mar 2006 | - | $1.64 M(-72.1%) |
| Dec 2005 | $5.94 M(+108.6%) | $5.87 M(>+9900.0%) |
| Sept 2005 | - | $35.90 K(+76.0%) |
| June 2005 | - | $20.40 K(+87.2%) |
| Mar 2005 | - | $10.90 K(-99.6%) |
| Dec 2004 | $2.85 M(+1831.5%) | $2.71 M(+6081.1%) |
| Sept 2004 | - | $43.90 K(-26.7%) |
| June 2004 | - | $59.90 K(+101.7%) |
| Mar 2004 | - | $29.70 K(-39.3%) |
| Dec 2003 | $147.40 K(-11.1%) | $48.90 K(+48.2%) |
| Sept 2003 | - | $33.00 K(+6.5%) |
| June 2003 | - | $31.00 K(-10.4%) |
| Mar 2003 | - | $34.60 K(-34.1%) |
| Dec 2002 | $165.80 K(-57.0%) | $52.50 K(+46.6%) |
| Sept 2002 | - | $35.80 K(-3.0%) |
| June 2002 | - | $36.90 K(-9.1%) |
| Mar 2002 | - | $40.60 K(-74.0%) |
| Dec 2001 | $385.80 K(+1.0%) | $156.20 K(+166.1%) |
| Sept 2001 | - | $58.70 K(-9.7%) |
| June 2001 | - | $65.00 K(-38.6%) |
| Mar 2001 | - | $105.80 K(-52.0%) |
| Dec 2000 | $381.90 K(-91.3%) | $220.30 K(+1312.2%) |
| Sept 2000 | - | $15.60 K(-79.9%) |
| June 2000 | - | $77.80 K(+14.1%) |
| Mar 2000 | - | $68.20 K(-63.0%) |
| Dec 1999 | $4.37 M(-52.5%) | $184.50 K(-68.8%) |
| Sept 1999 | - | $590.50 K(-56.6%) |
| June 1999 | - | $1.36 M(-39.1%) |
| Mar 1999 | - | $2.24 M |
| Dec 1998 | $9.21 M(+5502.1%) | - |
| Dec 1997 | $164.40 K(+272.8%) | - |
| Dec 1996 | $44.10 K | - |
FAQ
- What is Protalix BioTherapeutics annual total expenses?
- What is the all time high annual total expenses for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics quarterly total expenses?
- What is the all time high quarterly total expenses for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics quarterly total expenses year-on-year change?
What is Protalix BioTherapeutics annual total expenses?
The current annual total expenses of PLX is $55.03 M
What is the all time high annual total expenses for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high annual total expenses is $65.41 M
What is Protalix BioTherapeutics quarterly total expenses?
The current quarterly total expenses of PLX is $13.97 M
What is the all time high quarterly total expenses for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high quarterly total expenses is $18.09 M
What is Protalix BioTherapeutics quarterly total expenses year-on-year change?
Over the past year, PLX quarterly total expenses has changed by -$2.13 M (-13.25%)